Objective To compare the different types of physical artificial liver support system(ALSS) applied in the treatment of patients with early stage of chronic severe hepatitis in order to evaluate the therapeutic effect and look for the most effective one.Methods One hundred and twenty patients of chronic severe hepatitis B in early stage were randomly divided into 4 groups(each n=30).The patients in group 1 were treated by 3 000 ml plasma exchange;in group 2,by 2 000 ml plasma exchange combined with plasma adsorption for 2 hours;in group 3,only by plasma adsorption for 3 hours and in group 4,by molecular adsorbent re-circulating system(MARS).The observation time lasted for 2 weeks and the therapy twice a week,the interval between two times of treatment being 2-3 days.The improvement of symptoms,the fade away and rebound of icterus,the changes of albumin and prothrombin activity(PTA),side effects(anaphylaxis,hepatic encephalopathy,edema of conjunctiva,burp,fluid and electrolyte balance failure,changes of blood routine test and ammonia level,etc) were compared before and after the treatment.Results The symptoms of 27 cases in group 1 were improved,the rate of decrease of total bilirubin(TBil) of group 1 was 51.8% and the range of icterus rebound was 14.4% to 46.7% with comparatively more side effects.The symptoms of 24 cases of group 2 were improved,the rate of decrease of TBil in group 2 was 62.2% and the range of icterus rebound was 2.8% to 28.5% with comparatively less side effects.The symptoms of 16 cases of group 3 were improved,the rate of decrease of TBil in group 3 was 38.8% and the range of icterus rebound was 2.8% to 6.8% with less side effects.The symptoms of 26 cases of group 4 were improved,the rate of decrease of TBil in group 4 was 60.1% and the range of icterus rebound was 7.8% to 27.4% with comparatively more side effects,moreover the cost was higher than that in the other groups.Conclusion The method of reduced plasma exchange combined with plasma adsorption with macroporous resin used to cure chronic severe hepatitis at early stage has the characteristic of good effects for the fade away of icterus,little rebound of icterus and side effects.It is the reasonable method of artificial liver to cure the early stage of chronic severe hepatitis.

Objective The aim of the study is to discuss the application value of HA330-Ⅱ microporous resin plasma adsorption in liver support and the treatment of complications of chronic severe hepatitis.Methods The treatment group has 41 patients of chronic severe hepatitis B,which were treated for 3 times by HA330-Ⅱ microporous resin plasma adsorption.We compared the improvement of symptom,the fadeamay and rebound of icterus,the change of hepatic encepllalOpathy and brain oedema,the change of blood routine test,blood ammonia level,blood-gas analyzing result,cruor index,inflammatory factors(IL-1b,IL-6,IL-8,TNF-α,etc.),side effects,etc.The control group has 37 patients of the same type.Results HA330-Ⅱ microporous resin plasma adsorptioin is partly effective for the improvement of symptom,improvernent rate 43.9%,and without new discomfort due to the treatment. It obtains some extent fadeaway of icterus which has a low rebound,reduce TBiL(17.83±3.65)% and there be no statistics difference of rebound.It lowers the blood ammonia level and improves the hepatic encephalopathy and brain oedema.It absorbs cytokine IL-8.Atthough it has some extent effect to albunfin,blood paltelet,haemoglobin.Conclusion HA330-Ⅱ microporous resin plasma adsorption has good application value in the treatment of chronic severe hepatitis B.It is a new treatment choice of severe hepatitis.

16,95% CI 0.074-0.628 ,P<0.05) and diabetes mellitus history(RR=3.023,95% CI 0.998-9.157,P≤0.05).

UNC-51-like kinase 1 (ULK1), as a serine/threonine kinase, is an autophagic initiator in mammals and a homologous protein of autophagy related protein (Atg) 1 in yeast and of UNC-51 in Caenorhabditis elegans. ULK1 is well-known for autophagy activation, which is evolutionarily conserved in protein transport and indispensable to maintain cell homeostasis. As the direct target of energy and nutrition-sensing kinase, ULK1 may contribute to the distribution and utilization of cellular resources in response to metabolism and is closely associated with multiple pathophysiological processes. Moreover, ULK1 has been widely reported to play a crucial role in human diseases, including cancer, neurodegenerative diseases, cardiovascular disease, and infections, and subsequently targeted small-molecule inhibitors or activators are also demonstrated. Interestingly, the non-autophagy function of ULK1 has been emerging, indicating that non-autophagy-relevant ULK1 signaling network is also linked with diseases under some specific contexts. Therefore, in this review, we summarized the structure and functions of ULK1 as an autophagic initiator, with a focus on some new approaches, and further elucidated the key roles of ULK1 in autophagy and non-autophagy. Additionally, we also discussed the relationships between ULK1 and human diseases, as well as illustrated a rapid progress for better understanding of the discovery of more candidate small-molecule drugs targeting ULK1, which will provide a clue on novel ULK1-targeted therapeutics in the future.